Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma

PLoS Computational Biology

Volumn 6, Issue 5, 2010, Pages 1-19

  Fallahi Sichani, Mohammad ^a   Schaller, Matthew A ^b   Kirschner, Denise E ^b   Kunkel, Steven L ^b   Linderman, Jennifer J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASE CONTROL; GLYCOPROTEINS; IMMUNE SYSTEM; PROCESS CONTROL; SENSITIVITY ANALYSIS; TUMORS;

IMMUNE CELLS; IMMUNE RESPONSE; KEY PROCESS; MULTI-SCALES; MYCOBACTERIUM TUBERCULOSIS; PARTIAL DIFFERENTIAL EQUATION MODELS; PROINFLAMMATORY CYTOKINES; RECEPTOR BINDING; TUBERCULOSIS INFECTION; TUMOR NECROSIS FACTORS;

MACROPHAGES;

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EXPERIMENTAL MODEL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG GRANULOMA; LUNG TUBERCULOSIS; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PREDICTION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR BINDING; RECEPTOR DENSITY; SENSITIVITY ANALYSIS; STOICHIOMETRY; ALGORITHM; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CBA MOUSE; COMPUTER SIMULATION; DENDRITIC CELL; DRUG ANTAGONISM; GRANULOMA; IMMUNOLOGY; LYMPHOCYTE; MACROPHAGE; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; TUBERCULOSIS;

ALGORITHMS; ANIMALS; APOPTOSIS; COMPUTER SIMULATION; DENDRITIC CELLS; GRANULOMA; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED CBA; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULIN; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955478490     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000778     Document Type: Article

References (95)

1. Mortellaro A, Robinson L, Ricciardi-Castagnoli P (2009) Spotlight on mycobacteria and dendritic cells: Will novel targets to fight tuberculosis emerge? EMBO Mol Med 1: 19-29.
2. Algood HM, Chan J, Flynn JL (2003) Chemokines and tuberculosis. Cytokine Growth Factor Rev 14: 467-477.
3. Russell DG (2007) Who puts the tubercle in tuberculosis? Nat Rev Microbiol 5: 39-47.
4. Flynn JL (2004) Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84: 93-101.
5. Morel PA, Ta'asan S, Morel BF, Kirschner DE, Flynn JL (2006) New insights into mathematical modeling of the immune system. Immunol Res 36: 157-165.
6. Davis JM, Ramakrishnan L (2008) "The very pulse of the machine": The tuberculous granuloma in motion. Immunity 28: 146-148.
7. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, et al. (2006) Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell Microbiol 8: 218-232.
8. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, et al. (2004) Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 204: 217-228.
9. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, et al. (2006) Early events in mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 74: 3790-3803.
10. Turner OC, Basaraba RJ, Frank AA, Orme IM (2003) Granuloma formation in mouse and guinea pig models of experimental tuberculosis. In: Boros DL, ed. Granulomatous infections and inflammations: cellular and molecular mechanisms. Washington, D.C.: ASM Press. pp 65-84.
11. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, et al. (2008) Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28: 271-284.
12. Ulrichs T, Kaufmann SH (2006) New insights into the function of granulomas in human tuberculosis. J Pathol 208: 261-269.
13. Korner H, Sedgwick JD (1996) Tumour necrosis factor and lymphotoxin: Molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 74: 465-472.
14. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, et al. (2001) Biology of TACE inhibition. Ann Rheum Dis 60 Suppl 3: iii25-32.
15. Smith RA, Baglioni C (1987) The active form of tumor necrosis factor is a trimer. J Biol Chem 262: 6951-6954.
16. Vandenabeele P, Declercq W, Beyaert R, Fiers W (1995) Two tumour necrosis factor receptors: Structure and function. Trends Cell Biol 5: 392-399.
17. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, et al. (1998) TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-952.
18. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 2: 561-572.
19. Keane J, Shurtleff B, Kornfeld H (2002) TNF-dependent BALB/c murine macrophage apoptosis following mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-gamma independent manner. Tuberculosis (Edinb) 82: 55-61.
20. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, et al. (1997) Infection by mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 65: 298-304.
21. Algood HM, Lin PL, Yankura D, Jones A, Chan J, et al. (2004) TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during mycobacterium tuberculosis infection. J Immunol 172: 6846-6857.
22. Lin PL, Plessner HL, Voitenok NN, Flynn JL (2007) Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 12: 22-25.
23. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, et al. (2008) Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 76: 916-926.
24. Clay H, Volkman HE, Ramakrishnan L (2008) Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29: 283-294.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 345: 1098-1104.
26. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610.
27. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, et al. (2009) TNF neutralization results in disseminated disease during acute and latent mtb infection with normal granuloma structure. Arthritis Rheum;In press.
28. Marino S, Sud D, Plessner H, Lin PL, Chan J, et al. (2007) Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 3: 1909-1924.
29. Ray JC, Flynn JL, Kirschner DE (2009) Synergy between individual TNFdependent functions determines granuloma performance for controlling mycobacterium tuberculosis infection. J Immunol 182: 3706-3717.
30. Lauffenburger D, Linderman JJ (1993) Receptors: Models for binding, trafficking, and signaling. New York: Oxford University Press.
31. Rippley RK, Stokes CL (1995) Effects of cellular pharmacology on drug distribution in tissues. Biophys J 69: 825-839.
32. Tsujimoto M, Yip YK, Vilcek J (1985) Tumor necrosis factor: Specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci U S A 82: 7626-7630.
33. Imamura K, Spriggs D, Kufe D (1987) Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol 139: 2989-2992.
34. Vuk-Pavlovic S, Kovach JS (1989) Recycling of tumor necrosis factor-alpha receptor in MCF-7 cells. FASEB J 3: 2633-2640.
35. Pan W, Tu H, Yu C, Hsuchou H, Yang Y, et al. (2007) Differential role of TNF receptors in cellular trafficking of intact TNF. Cell Physiol Biochem 20: 559-568.
36. Bajzer Z, Myers AC, Vuk-Pavlovic S (1989) Binding, internalization, and intracellular processing of proteins interacting with recycling receptors. A kinetic analysis. J Biol Chem 264: 13623-13631.
37. Chensue SW, Kunkel SL (2003) Cytokines and chemokines in granulomatous inflammation. In: Boros DL, ed. Granulomatous infections and inflammations: cellular and molecular mechanisms. Washington, D.C.: ASM Press. pp 29-64.
38. Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC, et al. (1994) Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Pathol 145: 1105-1113.
39. Chensue SW, Warmington KS, Ruth JH, Lincoln P, Kunkel SL (1995) Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol 154: 5969-5976.
40. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL (1997) Mycobacterial and schistosomal antigen-elicited granuloma formation in IFNgamma and IL-4 knockout mice: Analysis of local and regional cytokine and chemokine networks. J Immunol 159: 3565-3573.
41. Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW (2001) Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigenelicited pulmonary granuloma formation. Am J Pathol 158: 1503-1515.
42. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95: 570-575.
43. Adamson GM, Billings RE (1994) Tumor necrosis factor: Receptor binding and expression of receptors in cultured mouse hepatocytes. J Pharmacol Exp Ther 269: 367-373.
44. Higuchi M, Aggarwal BB (1994) TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 152: 3550-3558.
45. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323-329.
46. Ehlers S (2003) Role of tumour necrosis factor (TNF) in host defence against tuberculosis: Implications for immunotherapies targeting TNF. Ann Rheum Dis 62 Suppl 2: ii37-42.
47. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117: 244-279.
48. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.
49. Jit M, Henderson B, Stevens M, Seymour RM (2005) TNF-alpha neutralization in cytokine-driven diseases: A mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Rheumatology (Oxford) 44: 323-331.
50. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, et al. (1995) A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181: 1205-1210.
51. Solomon KA, Covington MB, DeCicco CP, Newton RC (1997) The fate of pro- TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J Immunol 159: 4524-4531.
52. Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJ, et al. (2005) The met-196→arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 280: 5994-6004.
53. Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, et al. (1992) Biochemical properties of the 75-kDa tumor necrosis factor receptor. characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem 267: 21172-21178.
54. Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, et al. (2005) Contribution of transmembrane tumor necrosis factor to host defense against mycobacterium bovis bacillus calmette-guerin and mycobacterium tuberculosis infections. Am J Pathol 166: 1109-1120.
55. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int Stat Rev 62: 229-243.
56. Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254: 178-196.
57. Kinzer-Ursem TL, Linderman JJ (2007) Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling. PLoS Comput Biol 3: e6.
58. Chang ST, Linderman JJ, Kirschner DE (2008) Effect of multiple genetic polymorphisms on antigen presentation and susceptibility to mycobacterium tuberculosis infection. Infect Immun 76: 3221-3232.
59. Chang ST, Linderman JJ, Kirschner DE (2005) Multiple mechanisms allow mycobacterium tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages. Proc Natl Acad Sci U S A 102: 4530-4535.
60. Pocsik E, Mihalik R, Ali-Osman F, Aggarwal BB (1994) Cell density-dependent regulation of cell surface expression of two types of human tumor necrosis factor receptors and its effect on cellular response. J Cell Biochem 54: 453-464.
61. van Riemsdijk-Van Overbeeke IC, Baan CC, Knoop CJ, Loonen EH, Zietse R, et al. (2001) Quantitative flow cytometry shows activation of the TNF-alpha system but not of the IL-2 system at the single cell level in renal replacement therapy. Nephrol Dial Transplant 16: 1430-1435.
62. Fallahi-Sichani M, Linderman JJ (2009) Lipid raft-mediated regulation of Gprotein coupled receptor signaling by ligands which influence receptor dimerization: A computational study. PLoS One 4: e6604.
63. Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254: 178-196.
64. Filler SG, Solis NV, Guo J, Doellgast G, Ruiz-Garcia A, et al. (2007) Pharmacokinetics of murine p75-fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice. J Investig Dermatol Symp Proc 12: 52-56.
65. Chiu BC, Freeman CM, Stolberg VR, Hu JS, Komuniecki E, et al. (2004) The innate pulmonary granuloma: Characterization and demonstration of dendritic cell recruitment and function. Am J Pathol 164: 1021-1030.
66. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, et al. (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218-220.
67. Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, et al. (2007) Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 9: 623-628.
68. Hoang TT, Nansen A, Roy S, Billeskov R, Aagaard C, et al. (2009) Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with mycobacterium tuberculosis. PLoS One 4: e5928.
69. Menart V, Gaberc-Porekar V, Jevsevar S, Pernus M, Meager A, et al. (2000) Early events in TNFa-p55 receptor interations-experiments with TNF dimers. Pflugers Arch 439: R113-5.
70. Corti A, Fassina G, Marcucci F, Barbanti E, Cassani G (1992) Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J 284: 905-910.
71. Rangamani P, Sirovich L (2007) Survival and apoptotic pathways initiated by TNF-alpha: Modeling and predictions. Biotechnol Bioeng 97: 1216-1229.
72. Lipniacki T, Puszynski K, Paszek P, Brasier AR, Kimmel M (2007) Single TNFalpha trimers mediating NF-kappaB activation: Stochastic robustness of NF-kappaB signaling. BMC Bioinformatics 8: 376.
73. Hohmann HP, Remy R, Poschl B, van Loon AP (1990) Tumor necrosis factorsalpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding. J Biol Chem 265: 15183-15188.
74. Cheong R, Bergmann A, Werner SL, Regal J, Hoffmann A, et al. (2006) Transient IkappaB kinase activity mediates temporal NF-kappaB dynamics in response to a wide range of tumor necrosis factor-alpha doses. J Biol Chem 281: 2945-2950.
75. Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, et al. (2002) Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 115: 2757-2770.
76. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45-65.
77. Kundu M, Pathak SK, Kumawat K, Basu S, Chatterjee G, et al. (2009) A TNFand c-cbl-dependent FLIP(S)-degradation pathway and its function in mycobacterium tuberculosis-induced macrophage apoptosis. Nat Immunol 10: 918-926.
78. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, et al. (2003) Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9: 1039-1046.
79. Seah GT, Rook GA (2001) Il-4 influences apoptosis of mycobacterium-reactive lymphocytes in the presence of TNF-alpha. J Immunol 167: 1230-1237.
80. Kremer L, Estaquier J, Wolowczuk I, Biet F, Ameisen JC, et al. (2000) Ineffective cellular immune response associated with T-cell apoptosis in susceptible mycobacterium bovis BCG-infected mice. Infect Immun 68: 4264-4273.
81. Co DO, Hogan LH, Il-Kim S, Sandor M (2004) T cell contributions to the different phases of granuloma formation. Immunol Lett 92: 135-142.
82. Turner OC, Basaraba RJ, Orme IM (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with mycobacterium tuberculosis. Infect Immun 71: 864-871.
83. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, et al. (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131: 308-316.
84. Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, et al. (2007) Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 374: 1374-1388.
85. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, et al. (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195: 1643-1650.
86. Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34: 34-38.
87. Kirschner DE, Chang ST, Riggs TW, Perry N, Linderman JJ (2007) Toward a multiscale model of antigen presentation in immunity. Immunol Rev 216: 93-118.
88. Nugent LJ, Jain RK (1984) Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238-244.
89. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 98: 4628-4633.
90. Wenning LA, Murphy RM (1999) Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng 62: 562-575.
91. Chen KC, Kim J, Li X, Lee B (2008) Modeling recombinant immunotoxin efficacies in solid tumors. Ann Biomed Eng 36: 486-512.
92. Guler R, Olleros ML, Vesin D, Parapanov R, Garcia I (2005) Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to mycobacterium bovis BCG infection. Infect Immun 73: 3668-3676.
93. Watson VE, Hill LL, Owen-Schaub LB, Davis DW, McConkey DJ, et al. (2000) Apoptosis in mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol 190: 211-220.
94. Baxter LT, Yuan F, Jain RK (1992) Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data. Cancer Res 52: 5838-5844.
95. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668.